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Several miRNAs have been implicated in the development and progression of osteosarcoma (OS). In
this study, we found that miR-16 is downregulated in OS cell lines and tissues. Overexpression of
miR-16 suppresses OS cell proliferation and tumor growth in nude mice. Furthermore, we con-
ﬁrmed that IGF1R is a direct target of miR-16. Mechanistic investigation revealed that miR-16 over-
expression inhibits the Raf1–MEK1/2–ERK1/2 pathway. In clinical specimens, IGF1R levels inversely
correlate with miR-16 expression. Our results provide signiﬁcant clues regarding the role of miR-16
as a tumor suppressor by targeting IGF1R in OS.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction In the present study, we identiﬁed signiﬁcant downregulationOsteosarcoma (OS) is one of the most common primary sarcoma
of bone and a leading cause of cancer death due to its rapid prolifer-
ation among adolescents [1]. Despite the rapid development in
treatment strategies, the cure rate of patients carrying osteosar-
coma is still very poor. Therefore, there is an urgent need to develop
novel strategies for the diagnosis, treatment and prognosis of OS.
miRNAs (microRNAs) are a class of small endogenous non-cod-
ing RNA molecules, which regulate target-gene expression at post-
transcriptional levels [2,3]. Recent evidence has shown that about
half of human miRNAs are located in cancer-associated genomic
regions that are frequently ampliﬁed, deleted, or rearranged in
cancer, suggesting that some miRNAs may act as oncogenes or tu-
mor suppressors [4,5]. Oncogenic and tumor suppressor miRNAs
have been observed in OS, such as high expression of miR-20a,
miR-19a, miR-93 [6–8], as well as reduced expression of miR-
34a, miR-183 and miR-145 [9,10], which contribute to the devel-
opment and progression of OS. A recent study has shown that
miR-16 is also downregulated in OS tissues compared to healthy
bone tissue by miRNA microarray analysis [11]. Function and
mechanism of miR-16 as a tumor suppressor have been studied
in chronic lymphocytic lymphoma [12], pituitary adenomas [13],
breast and ovarian cancer [14,15]. However, the biological function
and molecular mechanism of miR-16 in OS remain to be unknown.of miR-16 in OS cell lines and tissues, and found that overexpres-
sion of miR-16 potently inhibited OS cell proliferation in vitro
and in vivo. In addition, we conﬁrmed IGF1R as a direct target of
miR-16 and explored the underlying mechanism of miR-16 in OS.
Our ﬁndings demonstrate a novel role of miR-16 in human OS.2. Materials and methods
2.1. Cell lines and clinical specimens
Four osteosarcoma cell lines, including HOS, KHOS, U2OS, and
MG-63, were obtained from the ATCC. Human osteoblast cell line
HOB was purchased from PromoCell (Heidelberg, Germany). The
OS cell lines were maintained in DMEM (Invitrogen, Carlsbad,
CA) supplemented with 10% fetal bovine serum. HOB cells were
cultured in osteoblast growth medium (PromoCell). Cells were
incubated at 37 C in humidiﬁed incubator containing 5% CO2.
Eighteen OS and the adjacent normal tissues were obtained
from patients who underwent surgery at Wuhan General Hospital
of Guangzhou Military Region, Wuhan, China. The study was ap-
proved by the Ethics Committee of Wuhan General Hospital of
Guangzhou Command, People’s Liberation Army, and written in-
formed consent was obtained from each patient.2.2. Quantitative real-time PCR (qRT-PCR)
For evaluating IGF1R expression, qRT-PCR was performed with
an ABI PRISM 7900 Sequence Detection System (Applied
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ward 50-GAGAAGGAGGAGGCTGAATACCG-30 and reverse 50-
GTGATGTTGTAGGTGTCTGCGGC-30. The relative level of miR-16
was determined using a mirVana™ qRT-PCR miRNA Detection Kit
(Ambion, Foster City, CA, USA) as described previously [16]. All
samples were normalized to the internal control (b-actin or U6)
and fold changes were calculated through 2DDCt analysis method.
2.3. Lentivirus production and infection, and oligonucleotide
transfection
The IGF1R shRNA was purchased from GeneChem (Shanghai,
China), and cloned into the pLVTHM vector. The oligonucleotides
used were 50-GATCCGGCCAGAAATGGAGAATAATTCAAGAGATTAT
TCTCCATTTCTGGCCTCA-30 and 50-AGCTTGAGGCCAGAAATGGA
GAATAATCTCTTGAATTATTCTCCATTTCTGGCCG-30. The pre-miR-16
sequence was cloned into the pCDH-CMV-MCS-EF1-coGFP vector.
The primers for pre-miR-16 were: 50-CCTGAATTCATAATACTGA
AAAGACTATCAATAAAACTG-30 (forward) and 50-CTTGGATCCG
TAAAGTAGCAGCACATAATGGTTTGTGGA-30 (reverse). Lentivirus
particles were harvested 48 h after pCDH-CMV-miR-16 or
pLVTHM-shIGF1R transfection with the corresponding packaging
plasmids into 293T cells. Then KHOS and U2OS cells were infected
with recombinant lentivirus-transducing units plus 10 mg/ml
polybrene (Sigma, St. Louis, Missouri, USA). The miR-16 antisense
inhibitor (anti-miR16) and negative control were purchased from
Ambion (Austin, TX). MG63 cells were transfected with anti-
miR16 and negative control using Lipofectamine 2000. Cells were
collected 48 h after transfection.
2.4. luciferase reporter assay
The wild-type and mutant 30-UTR fragments were cloned into
the downstream of the luciferase reporter gene in pGL3-control
vector. The primers were as the following: forward 50-TCCAC
GCGTCCACAACAGCAGTAAGAAGAAAAGC-30 and reverse 50-TTGC
TCGAGCCTAAGCAAAGGCAAGGGAAAGAGA-30 for IGF1R; forward
50-AGAACGCGTCCATTCTCG
TTTTAGGACTCTTCTT-30, reverse 50-CGTCTCGAGCAGGTTTGAAA
AATCCTACTGTCGC-30 for Kras; forward 50-CACACGCGTCACCACTT
TTCTGCTCCCTTTCTCC-30, reverse 50-GTCCTCGAGCAAAGGGATAGA
AAAGAAGGCAACA-30 for Raf1. For luciferase reporter assays, KHOS
and U2OS cells were transiently cotransfected with appropriate
reporter plasmid and a control Renilla luciferase vector in theFig. 1. The expression of miR-16 in OS cell lines and clinical specimens. (A) The relative e
by qRT-PCR. (B) The relative expression of miR-16 in 18 paired OS and adjacent norm
experiments.presence of either miR-16 or miR-control. 48 h after transfection,
cells were harvested and lysed, and luciferase activity was mea-
sured using the Dual-Luciferase Reporter Assay System (Promega,
Madison, WI, USA).
2.5. Cell proliferation assay and cell cycle analysis
The transfected cells were plated in 24-well plates at 5  103
per well and cultured for 1, 2, 3, 4 and 5 days. Cell counts were esti-
mated by trypsinizing the cells and performing analysis with a
Coulter counter (Beckman Coulter, Fullerton, CA, USA). For analysis
of cell cycle, 2  105 transfected cells were suspended in 1 ml solu-
tion containing 0.4 mM sodium citrate, 25 lg/ml propidium iodide
(PI), and 50 lg/ml RNase. The stained cells were analyzed in a FAC-
Scan ﬂow cytometer (BD Biosciences, USA) using the ModFit LT
program (BD Biosciences, USA).
2.6. Western blotting
Proteins were separated on 10% SDS–PAGE gel and transferred
to nitrocellulose membrane (Bio-RAD, Richmond, CA, USA). After
blocked with 5% non-fat milk, the membrane was incubated with
primary antibody against Kras, Raf1, p-Raf1, MEK1/2, p-MEK1/2,
ERK1/2, p-ERK1/2 or b-actin (Santa Cruz Biotechnology, CA, USA).
The membranes were then incubated with antimouse or antirabbit
IgG conjugated to horseradish peroxidase. Protein bands were
visualized using ECL reagents (Pierce, Rockford, IL, USA).
2.7. Tumor growth assay
Five-week-old male athymic BALB/c nude mice were purchased
from the Experimental Animal Center of the Third Military Medical
University. All animal studies complied with the Third Military
Medical University animal use guidelines and the protocols ap-
proved by the Third Military Medical University Animal Care Com-
mittee. 5  106 U2OS cells stably expressing miR-16 or miR-
control were injected subcutaneously to the skin under the front
legs of the mouse. The mice were observed over 4 weeks for tumor
formation. The tumor volume (V) was examined twice weekly with
a caliper and calculated by using the formula: V = (a  b2)/2, where
a is the larger and b is the smaller dimension of the tumor. After
the mice were sacriﬁced, the tumors were recovered and the wet
weights of each tumor were determined. The experiments were
performed using ﬁve mice per group.xpression of miR-16 in normal osteoblast HOB and four OS cell lines was measured
al bone tissues. Results represent the mean ratio between miR-16 and U6 from 3
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The SPSS 13.0 program was used for statistical analysis. Data
were expressed as mean ± S.D. of at least 3 independent experi-
ments. The differences between groups were analyzed using Stu-
dent0s t-test when comparing only two groups or assessed by
one-way analysis of variance when more than two groups were
compared. The relationship between IGF1R and miR-16 expression
was explored using Pearson v2 test. Data were considered to be
statistically signiﬁcant when P < 0.05 (⁄) and P < 0.01 (⁄⁄).
3. Results
3.1. miR-16 is downregulated in OS cells and tumors
To investigate the signiﬁcance of miR-16 in OS carcinogenesis,
we analyzed the expression of miR-16 in OS cell lines (HOS, KHOS,
U2OS, MG-63) and clinical specimens by qRT-PCR. The resultsFig. 2. miR-16 overexpression suppressed OS cell proliferation in vitro. (A) qRT-PCR analy
proliferation assay of KHOS and U2OS cells infected with Lv-miR16 or Lv-control, and MG
and U2OS cells infected with Lv-miR16 or Lv-control, and MG63 cells transfected withshowed that miR-16 expression was signiﬁcantly decreased in all
OS cell lines compared to HOB (Fig. 1A). Consistent with these
observations, OS clinical specimens expressed lower levels of
miR-16 compared to the adjacent normal bone tissues (Fig. 1B).
These results suggest that reduced expression of miR-16 is corre-
lated with OS carcinogenesis and that miR-16 might act as a tumor
suppressor in OS.
3.2. miR-16 inhibits OS cell proliferation in vitro
To explore the effect of miR-16 on OS cell proliferation, we ﬁrst
constructed miR-16-overexpressed OS cells by lentiviral vectors
carrying the pre-miR-16 gene. Signiﬁcant increase of miR-16
expression in KHOS and U2OS cells was conﬁrmed by qRT-PCR
(Fig. 2A). As shown in Fig. 2B, cell growth was signiﬁcantly de-
creased in miR-16-overexpressed cells compared to their corre-
sponding controls. Moreover, cell cycle analysis of miR-16-
overexpressed cells showed signiﬁcant increase in G0/G1 phasesis of miR-16 in KHOS and U2OS cells infected with Lv-miR16 or Lv-control. (B) Cell
63 cells transfected with anti-miR16 or anti-control. (C) Cell cycle analysis of KHOS
anti-miR16 or anti-control.
Fig. 3. IGF1R is a direct miR-16 target in OS cells. (A) Diagram of IGF1R 30UTR-containing reportor construct. Mutations were generated at the predited miR-16-binding site
located in the IGF1R 30-UTR. (B) Luciferase reporter assays in KHOS and U2OS cells. The wild-type or mutant reporter plasmids were co-transfected into KHOS and U2OS cells
which were infected by Lv-control or Lv-miR16. (C) qRT-PCR analysis of the expression of IGF1R. (D) Western blotting analysis of the expression of IGF1R. (E) Silencing of
IGF1R in U2OS cells was veriﬁed by Western blotting. Cell proliferation assay (F) and cell cycle analysis (G) in U2OS cells infected with Lv-miR16, Lv-shIGF1R or Lv-control.
Fig. 4. miR-16 regulates the expression of major molecules of the Raf1–MEK1/2–ERK1/2 pathway in OS cells. (A) The protein levels of Kras, Raf1, p-Raf1, MEK1/2, p-MEK1/2,
ERK1/2 and p-ERK1/2 were reduced by miR-16 overexpression or IGF1R silencing (left) in U2OS cells, and the levels of these moleculars were increased by anti-miR16
transfection in MG63 cells (right). (B) Diagram of Kras 30UTR-containing reportor construct. Mutations were generated at the predited miR-16-binding site located in the Kras
30-UTR. (C) Diagram of Raf1 30UTR-containing reportor construct. Mutations were generated at the predited miR-16-binding site located in the Raf1 30-UTR. (D) Luciferase
reporter assay. U2OS cells were co-transfected with luciferase reporter plasmids containing the WT or Mut miR-16 target sites in the Kras 30UTR with miR-16 or miR-control
precursors. (E) Luciferase reporter assay. U2OS cells were co-transfected with luciferase reporter plasmids containing the WT or Mut miR-16 target sites in the Raf1 30UTR
with miR-16 or miR-control precursors.
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moted cell growth and cell cycle G1/S transition in MG63 cells
(Fig. 2B and C). These results suggest that miR-16 can suppress
OS cell proliferation in vitro.
3.3. IGF1R is a direct target of miR-16 in OS cells
To understand the underlying mechanism of growth inhibition
induced by miR-16, we searched for the potential targets of miR-16
using TargetScan and Pictar. Among the predicted genes, we wereparticularly interested in IGF1R because it was closely correlated
with cancer cell proliferation. To verify IGF1R is a direct target of
miR-16, IGF1R 30-UTR containing wild-type or mutant miR-16-
binding site was cloned downstream of the luciferase reporter gene
(Fig. 3A). Luciferase reporter assays showed that miR-16 overex-
pression signiﬁcantly repressed the relative luciferase activity in
KHOS and U2OS cells when the plasmid contains wild-type IGF1R
30-UTR; however, the luciferase activity was unaffected when the
30-UTR contained mutant binding site (Fig. 3B). Consistently, qRT-
PCR and Western blotting analysis showed that miR-16
Fig. 5. miR-16 overexpression suppresses OS tumorigenesis in vivo. (A) Representative picture of tumors formed in nude mice. U2OS cells infected with Lv-miR16 produced
smaller tumors than control cells. (B) Growth curve of tumor volumes. The tumor volume was signiﬁcantly reduced by the overexpression of miR-16. Each data point
represents the mean ± S.D. of 5 mice. (C) The weight of tumors. The average tumor weight was signiﬁcantly reduced by the overexpression of miR-16. (D) The protein levels of
IGF1R, Kras, Raf1, p-Raf1, MEK1/2, p-MEK1/2, ERK1/2 and p-ERK1/2 were decreased in miR-16-overexpressed tumors.
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cells (Fig. 3C and D). In contrast, anti-miR16 transfection increased
IGF1R levels in MG63 cells (Fig. 3C and D).
Based on the results above, we hypothesized that miR-16 might
reduce OS cell proliferation by repressing IGF1R expression. To test
this hypothesis, we performed loss-of-function studies. As shown in
Fig. 3E, signiﬁcant inhibition of IGF1R expression in U2OS cells was
veriﬁed by Western blotting. Silencing of IGF1R led to cell growth
inhibition (Fig. 3F) and cell-cycle arrest (Fig. 3G), which was similar
to those induced by miR-16 overexpression. These results demon-
strate that IGF1R is a direct target of miR-16 in OS cells.
3.4. miR-16 suppresses the Raf1–MEK1/2–ERK1/2 pathway in OS cells
Given that IGF1R can activate many downstream genes closely
associated with malignant cell proliferation, such as Kras, Raf1,
MEK1/2 and ERK1/2, which were key components of the Raf1-
MEK1/2-ERK1/2 pathway, we further evaluated the potential effect
of miR-16 on these molecules in OS cells. As illustrated in Fig. 4A,the levels of these molecules and corresponding phosphorylated
molecules were down-regulated in miR-16-overexpressed U2OS
cells. These ﬁndings were also conﬁrmed by using shIGF1R. We
also observed that knockdown of miR-16 MG63 cells increased
the levels of all these moleculars above (Fig. 4A, right). These re-
sults demonstrate that miR-16 may be an important regulator in
the Raf1–MEK1/2–ERK1/2 pathway.
Given the above observations, we wondered whether there is
other targets of miR-16 in the Raf1–MEK1/2–ERK1/2 pathway.
Using TargetScan, another two miR-16 target sites were found in
Kras and Raf1 30-UTR segments respectively (Fig. 4B and C). The
relative luciferase activity of these reporters contained the miR-
16 binding sites but not the corresponding mutant counterpart
was signiﬁcantly reduced in miR-16-overexpressed U2OS cells
(Fig. 4D and E). These results indicate that miR-16 regulates the
expression of IGF1R, Kras and Raf1 by directly binding to the 30-
UTR target sites, supporting our conclusion that miR-16 can sup-
press OS cell proliferation by regulating Raf1–MEK1/2–ERK1/2
pathway.
Fig. 6. Expression of IGF1R was upregulated in OS tissues and negatively correlated with miR-16 levels. (A) Relative expression of IGF1R in 18 OS tissues and the adjacent
normal tissues using qRT-PCR analysis. (B) Correlation analysis of miR-16 and IGF1R expression was performed by Pearson v2 test in 18 OS tissues.
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To further determine whether miR-16 could suppress OS cell
growth in vivo, U2OS cells stably expressing miR-16 or miR-control
were injected subcutaneously to the skin under the front legs of
the mice. The tumor growth was closely monitored. As shown in
Fig. 5A and B, the tumor size and volume were markedly reduced
in miR-16-overexpressed tumors compared to control tumors.
More than 2-fold decrease in tumor weight was observed in miR-
16-overexpressed tumors compared to controls (Fig. 5C). More-
over, the levels of IGF1R, Kras, Raf1, p-Raf1, MEK1/2, p-MEK1/2,
ERK1/2, and p-ERK1/2 were reduced compared to controls
(Fig. 5D).
3.6. IGF1R is upregulated in OS tissues and inversely correlated with
miR-16 levels
We further examined the levels of miR-16 and IGF1R in 18 OS
tissues and the adjacent normal tissues. As shown in Fig. 6A, the
average expression of IGF1R was signiﬁcantly higher in OS tissues
compared to the adjacent normal tissues. Correlation analysis indi-
cated that IGF1R expression was reduced along with miR-16
upregulation in these 18 pairs of OS tissues (R2 = 0.794, Pearson
v2 test, Fig. 6B).
4. Discussion
miR-16 is a member of the miR-16 family, which is composed of
miR-15a, miR-15b, and miR-16. This family is known to act as tu-
mor suppressors and has been shown to play important roles in
inhibiting cell proliferation, promoting apoptosis, and suppressing
tumorigenicity [16,17]. For instance, Bonci et al [18] identiﬁed that
miR-15a and miR-16 overexpression resulted in growth arrest,
apoptosis and marked regression of prostate tumor xenografts. In
osteosarcoma, a preliminary study has shown that miR-16 is
downregulated by microarray analysis [11]. Our results variﬁed
the decreased expression of miR-16 in OS cell lines and OS tissues.
Moreover, we found that miR-16 could inhibit cell growth and in-
duce a G0/G1 arrest in OS cells, and suppress tumorigenesis in a
murine model of OS xenograft, suggesting its potential tumor sup-
pressor role in OS.
Similar to classical transcription factors, miRNAs exert their
functionality through regulating speciﬁc target genes. Of note,
one miRNA can regulate hundreds of target genes concomitantly.
miR-16 family can induce apoptosis and cell cycle arrest in G1 byrepressing speciﬁc target genes, including Bcl-2 and CCNE1
[14,19]; miR-16 also inhibited cell proliferation via downregulat-
ing ARL2 and Bmi-1 [15,20]. In this study, potential targets of
miR-16 were analyzed using different prediction algorithms.
Among a panel of candidate targets, IGF1R was further experimen-
tally validated as a miR-16 target in OS.
Insulin-like growth factor-1 receptor (IGF1R) is a receptor tyro-
sine kinase that mediates IGF1-induced signaling events and has
pivotal roles in cellular processes such as proliferation, cell migra-
tion and differentiation [21]. In recent years, mounting evidence
indicates that IGF1R may be involved in tumorigenesis in many
cancers, including gastric and breast cancer [22,23]. In our studies,
we demonstrated that miR-16 inhibited IGF1R expression, and
conﬁrmed that IGF1R was a direct target of miR-16 in OS cells.
Moreover, we found that silencing of IGF1R induced cell growth
inhibition and a G0/G1-phase arrest similar to the phenotypes in-
duced by miR-16 overexpression. These results suggested that the
growth suppressive effect of miR-16 was at least partly mediated
by repressing IGF1R expression.
Since IGF1R is a major component in the activation of Raf1–
MEK1/2–ERK1/2 pathway, which is related to tumorigenesis,
metastasis and apoptosis in many cancers [24,25], to further ex-
plore the molecular mechanisms of growth inhibition induced by
miR-16, we examined the expression of major molecules of the
Raf1–MEK1/2–ERK1/2 pathway. Our results demonstrated that
the levels of Kras, Raf1, MEK1/2, ERK1/2 and corresponding phos-
phorylated molecules were downregulated in miR-16-overexpres-
sed OS cells and xenograft tumors. Meanwhile, two major
molecules Kras and Raf1 in this pathway were also conﬁrmed to
be potential targets of miR-16 using luciferase assays. Therefore,
we inferred that miR-16 may play important roles in inhibiting
OS cell proliferation through downregulating multiple target genes
in the Raf1–MEK1/2–ERK1/2 pathway.
In summary, this study provides the ﬁrst evidence that overex-
pression of miR-16 inhibits OS cell growth by regulating IGF1R/
Kras/Raf1/MEK/ERK pathway both in vitro and in vivo. Our ﬁndings
on miR-16 are encouraging and suggest that exogenous overex-
pression of miR-16 could be a potential approach for the treatment
of OS in future.
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